Thursday, April 11, 2013
Agios Pharmaceuticals Inc. has
reported the first mutant-selective inhibitors of the metabolic enzymes IDH1
and has shown that the molecules have a therapeutic effect in preclinical
cancer models.1,2 The company also announced a partnership with Foundation Medicine Inc. to
develop companion diagnostics to identify patients with cancer who have the
Kotz, J. SciBX 6(14); doi:10.1038/scibx.2013.328 Published online
April 11, 2013
1. Wang, F. et al.
Science; published online April 4, 2013; doi:10.1126/science.1234769 Contact:
Katharine E. Yen, Agios Pharmaceuticals Inc., Cambridge, Mass. e-mail: firstname.lastname@example.org
2. Rohle, D. et al.
Science; published online April 4, 2013; doi:10.1126/science.1236062 Contact:
Katharine E. Yen, Agios Pharmaceuticals Inc., Cambridge, Mass. e-mail: email@example.com Contact:
Ingo K. Mellinghoff, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
3. Dang, L. et al.
Nature 462, 739-744 (2009)
4. Ward, P.S. et al.
Cancer Cell 17, 225-234 (2010)
AND INSTITUTIONS MENTIONED
Agios Pharmaceuticals Inc., Cambridge, Mass.
(NASDAQ:CELG), Summit, N.J.
Foundation Medicine Inc., Cambridge, Mass.
Massachusetts General Hospital, Boston, Mass.